Skip to content

Search

Lab results confirm promise of new immunotherapy gel for kids cancer

Newly published research from The Kids Research Institute Australia and The University of Western Australia has found a gel applied during surgery to treat sarcoma tumours is both safe and highly effective at preventing the cancer from growing back.

Why timing matters: How tumours respond to immunotherapy treatments over time

Researchers have identified key differences between cancers that respond to immunotherapy and those that do not.

Researchers narrow down field of new treatments for most common childhood brain cancer

Cancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.

Biobank funding supports valuable research resources

Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

The Kids Cancer Researcher wins prestigious Cancer Council WA award

The Kids Research Institute Australia cancer researcher, Dr Jason Waithman, has been named Cancer Council WA’s 2021 Cancer Researcher of the Year.

WA Kids Cancer Centre

The WA Kids Cancer Centre brings together clinicians and researchers working together to defeat childhood cancer.

Advancing hope for children with hard-to-treat leukaemia

Dr Sébastien Malinge has received a Stan Perron Charitable Foundation Research Fellowship for his pioneering research, which is paving the way for safer, targeted therapies for children with hard-to-treat leukaemia

World-first research to transform outcomes for First Nations children with cancer

A first of its kind research program at The Kids Research Institute Australia aims to develop new strategies to better treat First Nations children with cancer.

WA Kids Cancer Centre researchers appointed to Brain Cancer Expert Advisory Panel

Dr Jessica Buck and Associate Professor Raelene Endersby have been appointed to the prestigious Australian Brain Cancer Mission Expert Advisory Panel.

IDH-mutant gliomas in children and adolescents - from biology to clinical trials

Gliomas account for nearly 30% of all primary central nervous system (CNS) tumors in children and adolescents and young adults (AYA), contributing to significant morbidity and mortality. The updated molecular classification of gliomas defines molecularly diverse subtypes with a spectrum of tumors associated with age-distinct incidence.